Evidence map›Paper›PMID 34680987›Full record

ReviewGenes2021

Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.

Yun-Hsin Tang, Chiao-Yun Lin, Chyong-Huey Lai

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yun-Hsin TangDepartment of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Branch and Chang Gung University College of Medicine, Taoyuan 333, Taiwan.
Chiao-Yun LinDepartment of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Branch and Chang Gung University College of Medicine, Taoyuan 333, Taiwan.
Chyong-Huey LaiDepartment of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Branch and Chang Gung University College of Medicine, Taoyuan 333, Taiwan.ORCID 0000-0002-9977-9645
Chang Gung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the advent of next-generation sequencing (NGS), The Cancer Genome Atlas (TCGA) research network has given gynecologic cancers molecular classifications, which impacts clinical practice more and more. New cancer treatments that identify and target pathogenic abnormalities of genes have been in rapid development. The most prominent progress in gynecologic cancers is the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors, which have shown breakthrough benefits in reducing hazard ratios (HRs) (HRs between 0.2 and 0.4) of progression or death from

Indexed as

MutationFemaleGenital Neoplasms, FemaleHigh-Throughput Nucleotide SequencingHumansPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerase Inhibitorsendometrial cancergynecologic cancerhomologous recombination repairmismatch repairovarian cancer

Identifiers

PMID34680987
PMCPMC8535522
OpenAlexW3207399281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.